Biography

Dr. Kenji Kabashima

Graduate School of Medicine

Kyoto University, Japan

Associate Professor


Email: [email protected]


Qualifications

2003 Ph.D., Faculty of Medicine, Kyoto University

1996 M.D., Faculty of Medicine, Kyoto University


Publications (selected)

  1. Jutel, M., Agache, I., Zemelka‐Wiacek, M., Akdis, M., Chivato, T., Del Giacco, S., ... & Akdis, C. A. (2023). Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. Allergy, 78(11), 2851-2874.
  2. Beck, L. A., Cork, M. J., Amagai, M., De Benedetto, A., Kabashima, K., Hamilton, J. D., & Rossi, A. B. (2022). Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innovations, 2(5), 100131.
  3. Luger, T., Amagai, M., Dreno, B., Dagnelie, M. A., Liao, W., Kabashima, K., ... & Schmuth, M. (2021). Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. Journal of dermatological science, 102(3), 142-157.
  4. Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021). Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council. Journal of Allergy and Clinical Immunology, 147(4), 1174-1190.
  5. Akdis, C. A., Arkwright, P. D., Brüggen, M. C., Busse, W., Gadina, M., Guttman‐Yassky, E., ... & Palomares, O. (2020). Type 2 immunity in the skin and lungs. Allergy, 75(7), 1582-1605.
  6. Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020). Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. New England Journal of Medicine, 383(2), 141-150.
  7. Chakarov, S., Lim, H. Y., Tan, L., Lim, S. Y., See, P., Lum, J., ... & Ginhoux, F. (2019). Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science, 363(6432), eaau0964.
  8. Kabashima, K., Honda, T., Ginhoux, F., & Egawa, G. (2019). The immunological anatomy of the skin. Nature Reviews Immunology, 19(1), 19-30.
  9. Seidel, J. A., Otsuka, A., & Kabashima, K. (2018). Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Frontiers in oncology, 8, 86.
  10. Kabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Wollenberg, A., Galus, R., ... & Ruzicka, T. (2018). Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. Journal of Allergy and Clinical Immunology, 142(4), 1121-1130.
  11. Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., ... & Kabashima, K. (2017). Anti–interleukin-31 receptor A antibody for atopic dermatitis. New England Journal of Medicine, 376(9), 826-835.
  12. Yoshiki, R., Kabashima, K., Sugita, K., Atarashi, K., Shimauchi, T., and Tokura, Y. 2009. IL-10-producing Langerhans cells and regulatory T cells are responsible for depressed contact hypersensitivity in grafted skin. J Invest Dermatol 129:705-713.
  13. Nakashima, D., Kabashima, K.*, Sakabe, J., Sugita, K., Kobayashi, T., Yoshiki, R., and Tokura, Y. 2008. Impaired initiation of contact hypersensitivity by FTY720. J Invest Dermatol 128:2833-2841.
  14. Mori, T., Kabashima, K.*, Yoshiki, R., Sugita, K., Shiraishi, N., Onoue, A., Kuroda, E., Kobayashi, M., Yamashita, U., and Tokura, Y. 2008. Cutaneous hypersensitivities to hapten are controlled by IFN-gamma-upregulated keratinocyte Th1 chemokines and IFN-gamma-downregulated langerhans cell Th2 chemokines. J Invest Dermatol 128:1719-1727.
  15. Koga, C., Kabashima, K.*, Shiraishi, N., Kobayashi, M., and Tokura, Y. 2008. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128:2625-2630.
  16. Nagamachi, M., Sakata, D., Kabashima, K. (equally contributed 1stauthor), Furuyashiki, T., Murata, T., Segi-Nishida, E., Soontrapa, K., Matsuoka, T., Miyachi, Y., and Narumiya, S. 2007. Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1. J Exp Med 204:2865-2874.
  17. Kabashima, K.*, Shiraishi, N., Sugita, K., Mori, T., Onoue, A., Kobayashi, M., Sakabe, J., Yoshiki, R., Tamamura, H., Fujii, N., et al. 2007. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol 171:1249-1257.
  18. Kabashima, K., Haynes, N.M., Xu, Y., Nutt, S.L., Allende, M.L., Proia, R.L., and Cyster, J.G. 2006. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 203:2683-2690.
  19. Kabashima, K., Banks, T.A., Ansel, K.M., Lu, T.T., Ware, C.F., and Cyster, J.G. 2005. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22:439-450.
  20. Katagiri, K., Ohnishi, N., Kabashima, K., Iyoda, T., Takeda, N., Shinkai, Y., Inaba, K., and Kinashi, T. 2004. Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking. Nat Immunol 5:1045-1051
  21. Kabashima, K., Sakata, D., Nagamachi, M., Miyachi, Y., Inaba, K., and Narumiya, S. 2003. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 9:744-749.
  22. Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D., Yoshida, N., Katagiri, K., Kinashi, T., Tanaka, T., Miyasaka, M., et al. 2003. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 4:694-701.
  23. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., et al. 2002. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109:883-893.
  24. Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., Sugimoto, Y., Kobayashi, T., Ushikubi, F., Aze, Y., et al. 2000. Prostaglandin D2 as a mediator of allergic asthma. Science 287:2013-2017.
  25. Taga, K., Yamauchi, A., Kabashima, K., Bloom, E.T., Muller, J., and Tosato, G. 1996. Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood 87:2411-2418.


Profile Details

https://www.kyoto-u.ac.jp/en/news/2023-11-27
https://scholar.google.com/citations?user=5uwXXKAAAAAJ&hl=en&oi=ao
https://orcid.org/0000-0002-0773-0554

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top